Choose Your Country or Region

SN-38

Name: SN-38
Brand: Selleck Chemicals
SKU: S4908
Rating: 5 (40 reviews)

Catalog No.S4908 Synonyms: NK012

For research use only.

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

CAS No. 86639-52-3

Selleck's SN-38 has been cited by 40 publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Related Compound Libraries

Biological Activity

Description

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Targets

Topo I ^[1]
(Cell-free assay)

In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human DU145 prostate cell line	NFzt[XNRem:uaX\ldoF1cW:wIHHzd4F6			NVvPWpoySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSCycn;zeIF1\SClZXzsJIxqdmVuIFnDOVA:OTNibl2=	M4\Fc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEm4NlE3Lz5zMES5PFIyPjxxYU6=
human MCF-7 breast cell line	NW\jR3BNWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRj23JIJz\WG\|dDDj[YxtKGyrbnWsJGlEPTB;MD6zO{DPxE1?	M3PRS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEm4NlE3Lz5zMES5PFIyPjxxYU6=
human SKOV-3 ovarian cell line	MorBVJJwdGmoZYLheIlwdiCjc4PhfS=>			MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[tN{BwfmG{aXHuJINmdGxibHnu[UwhUUN3ME2wMlczKM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human breast cancer cell line (SK-BR-3)	MkLZR5l1d3SxeHnjxsBie3OjeR?=			NX;Z[4FwUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxtKGyrbnWgLHNMNUKULUOpMEBKSzVyPUSgcm0>	M2fhOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human lung cancer cell line (H128)	MYDDfZRwfG:6aXRCpIF{e2G7			M1PYemlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9OkBvVQ>?	M{DheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human stomach cancer cell line (MKN45)	MYTDfZRwfG:6aXRCpIF{e2G7			MWLJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDzeI9u[WOqIHPhcoNmeiClZXzsJIxqdmViKF3LUlQ2MSxiSVO1NF05KG6P	M2\VT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human ovarian cancer cell line (SK-OV-3)	NEj6NZhEgXSxdH;4bYPDqGG\|c3H5			MVnJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsJIxqdmViKGPLMW9XNTNrLDDJR\|UxRTFzIH7N	NFnCOI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN\|Q2Pjl:L3G+
human colon cancer cell line (WiDr)	M3LTUWN6fG:2b4jpZ:Kh[XO\|YYm=			NGDWSW9KdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscEBtcW6nIDjXbWRzMSxiSVO1NF0yPCCwTR?=	MoXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (A549)	MYHDfZRwfG:6aXRCpIF{e2G7			NHTTXohKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFG1OFkq	MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
NSCLC-H460	NHnmepFEgXSxdH;4bYPDqGG\|c3H5			NIrsVJVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwu[2WubDDseY5oKGOjcnPpco9u[SClZXzsJIxqdmViSES2NEApVlOFTFOtTFQ3OCluIFnDOVA:QDBibl2=	MoflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3NkO5NlUoRjFzNU[zPVI2RC:jPh?=
PC-3 carcinoma cell line	NIPLeHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MomxR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHfyc5d1cCCxZjDoeY1idiCycn;zeIF1\SCSQz2zJINiemOrbn;tZUBk\WyuIHzpcoUtKEmFNUC9N\|UvPiCwTR?=	NHLOTGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI{OCd-MUW0OVQzOzB:L3G+
human HCT116 colon cancer cell line	M1:0b2Z2dmO2aX;uJIF{e2G7			MV7Jcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBJS1RzMU[gZ49td25iY3HuZ4VzKGOnbHygcIlv\SxiSVO1NF04KG6P	NWewTndYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human Bel-7402 liver cancer cell line	NXHvV25uTnWwY4Tpc44h[XO\|YYm=			MmnrTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hSmWuLUe0NFIhdGm4ZYKgZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD1\|LkG5JO69VQ>?	NVn1emN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human tumor HL60 cell-line	MWnGeY5kfGmxbjDhd5NigQ>?		NHryZnk{KGSjeYO=	NFr3SlBKdi24aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36g[o9zKGi3bXHuJJR2dW:{IFjMOlAh[2WubD3sbY5mKHejczDk[ZRmem2rbnXkJJV{cW6pIGPSRkBie3OjeTDh[pRmeiB\|IHThfZMhd2ZiaX7jeYJifGmxbjygTWM2OD1zOTDuUS=>	M3LYcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUGzPVk3Lz5zNUmxN\|k6PjxxYU6=
human H460 cell	NIfheFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NYfPbGk{UW6qaXLpeIlwdiCxZjDoeY1idiCKNE[wJINmdGxiZ4Lve5RpNCCLQ{WwQVgxKG6P	NH;hO2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmxN\|cxPid-MU[5NVM4ODZ:L3G+
MDA-MB-435	Mly4SpVv[3Srb36gZZN{[Xl?			MXnJcohq[mm2aX;uJIFo[Wmwc4SgUWRCNU2ELUSzOUBUKGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMhcW5idHjlJIFje2WwY3Wgc4Yh[WykdX3pckwhUUN3MDC9JFAvODB3IN88UU4>	MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTFyNUK4NFIoRjFzMEWyPFAzRC:jPh?=
MDA-MB-435	NGfsb3hHfW6ldHnvckBie3OjeR?=			MlftTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N\|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBxemW\|ZX7j[UBw\iB\|MDDt[{9uVCCKU1GsJGlEPTBiPTCwMlA2KM7:TT6=	NGLTXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUC1NlgxOid-MUGwOVI5ODJ:L3G+
PC-6/SN2-5H	MWTGeY5kfGmxbjDhd5NigQ>?			M1HrUHRRZ1SUQV7TVG9TXEWUOjD1dJRic2ViaX6gcYVu[nKjbnWgeoV{cWOuZTDmdo9uKFCFLU[vV24zNTWKIHPlcIx{NCCNbTC9JFQh\|ryPLh?=	NYnVT2xzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG2PFg6QDJpPkGxOlg5QTh{PD;hQi=>
HT-29	MVrGeY5kfGmxbjDhd5NigQ>?			NXmzS4d4UW5idnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJJJmeXWrcnXkJIFo[Wmwc4SgTHQuOjliaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{NCCLQ{WwJF0hOC5yMkezJO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZzN{myO{c,OTJ4MUe5Nlc9N2F-
SaoS2	NEnYWmJHfW6ldHnvckBie3OjeR?=			MYrUVH9VWkGQU2DPVnRGWjpiZIL1[{Bz\XOrc4ThcoNmMEmvYYTpcoljKG2nc4nsZZRmMSCrbjDCR3JRNWW6cILld5NqdmdiU3HvV\|Ih[2WubIOsJGlEPTBiPTCwMlE4PiEQvF2u	Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVyNUm4PFEoRjF3MEW5PFgyRC:jPh?=
DU145	NF\OT41CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVPBdmFwQTZiaILz	MmTMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB7NjDodpMtKEmFNUCgQUAxNjByNDFOwG0v	NUjtNopTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyO\|YyPDFpPkG4Nlc3OTRzPD;hQi=>
MIA PaCa	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmPSPVYhcHK\|	M3nQVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBJHBiS2FiY3XscJMh[W[2ZYKgPVYhcHK\|LDDJR\|UxKD1iMD6wNFYh\|ryPLh?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
HT29	MoW3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn3yPVYhcHK\|	M1X6NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiB7NjDodpMtKEmFNUCgQUAxNjBzMjFOwG0v	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
H460	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHTLb4cyKGi{	MmC4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKNE[wJINmdGy\|IHHmeIVzKDFiaIKgc4Yh\HK3ZzDlfJBwe3W{ZTDt[YF{fXKnZDDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ{IN88UU4>	M4Hw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEK0NVM{Lz5zOESyOFE{OzxxYU6=
HT29	M1noPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYGxJIhz	NEjDN4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgZYZ1\XJiMTDodkBw\iCmcoXnJIV5eG:\|dYLlJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwNkeg{txONg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NEGzN{c,OTh2MkSxN\|M9N2F-
HT29	NXnjO5dUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NV3vO5lrOSCqch?=	NX7qWFhmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS1KSIH;2[ZJmgHC{ZYPzbY5oKG2rdH;4ZY51em:wZT3y[ZNqe3SjboSgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOTFwNTFOwG0v	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MkSxN\|MoRjF6NEK0NVM{RC:jPh?=
H460	NEm4XHJEgXSxdH;4bYNqfHliYYPzZZk>			MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzMEBKSzVyIE2gNE4zOiEQvF2u	NG\INYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE2Oyd-MUi0N\|QyPTN:L3G+
A549	MofIR5l1d3SxeHnjbZR6KGG\|c3H5			MmHIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR\|UxKD1iMD6wPEDPxE1w	Mor1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
HT-29	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=			NEfNSnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4yOiEQvF2u	M1q0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUi2PFA4Lz5zOEm4OlgxPzxxYU6=
PC6	NHH3d4RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnLJOkBl[Xm\|	NWi5UndQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Yh[2WubIOgZ4FzenmrbnegdHJEKGGodHXyJFYh\GG7czygTWM2OCB;IECuNFAxPDNizszNMi=>	NHnnUlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK1OFg1Oyd-MUmyOVQ5PDN:L3G+
HCT116	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGPGWWM{KGSjeYO=	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB\|IHThfZMtKEmFNUCgQUAxNjByMEW1JO69VS5?	M4TFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
QG56	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVrjc4R7OyCmYYnz	Mmi4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCTR{W2JINmdGy\|IHHmeIVzKDNiZHH5d{whUUN3MDC9JFAvODB{ODFOwG0v	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NUS4OFMoRjF7MkW0PFQ{RC:jPh?=
NCI-H460	NX20e45uSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MV[zJIRigXN?	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NEA:KDBwMECzN{DPxE1w	M{TxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
BCRP	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWi2JIRigXN?	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDlfJBz\XO\|aX7nJGJEWlBiY3XscJMh[W[2ZYKgOkBl[Xm\|LDDJR\|UxKD1iMD6wNFUyKM7:TT6=	NUnWOotURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR\|PD;hQi=>
KB3-1	NUPPXZBRS3m2b4TvfIlkcXS7IHHzd4F6		MUe0JIRigXN?	M{T6SGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRibXX0bI9lNCCLQ{WwJF0hOC5yMESg{txONg>?	MkfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MEOzNFYoRjF7M{CzN\|A3RC:jPh?=
KBV1	Mnn1R5l1d3SxeHnjbZR6KGG\|c3H5		NWXEbXRPPCCmYYnz	NXH6W4c1S3m2b4TvfIlkcXS7IHHnZYlve3RiTVTSNUBwfmW{ZYjwdoV{e2mwZzDoeY1idiCNQm[xJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCPVGSgcYV1cG:mLDDJR\|UxKD1iMD6wOFYh\|ryPLh?=	NWW1RYtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N\|A{OzB4PD;hQi=>
KBH5.0	MlTaR5l1d3SxeHnjbZR6KGG\|c3H5		MVW0JIRigXN?	NXfDd3BrS3m2b4TvfIlkcXS7IHHnZYlve3RiQlPSVEBwfmW{ZYjwdoV{e2mwZzDoeY1idiCNQli1MlAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IF3UWEBu\XSqb3SsJGlEPTBiPTCwMlMh\|ryPLh?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyM{OwOkc,OTl\|MEOzNFY9N2F-
NCI-H460	MkTwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUKxJIhz	NF3JdZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJJNpd3K2IITldo0h\Xiyb4P1doUh\m:{IEGgbJIhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHnuJIRzfWdvZoLl[UBu\WSrdX2sJGlEPTBiPTCwMlE{KM7:TT6=	MlPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{C3NlAoRjF7NUOwO\|IxRC:jPh?=
A549/ATCC	MY\BcpRqfHWvb4KgZZN{[Xl?			NV\FWWpSSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QS:DVFPDJINmdGy\|IHL5JHNTSiCvZYToc4QtKEmFNUCgQUAxNjB6ODFOwG0v	NH3GU3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ5Oyd-MUm1OFE1QDN:L3G+
HT-29	NWTLeYZ3SW62aYT1cY9zKGG\|c3H5			M4nNbWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIJ6KFOUQjDt[ZRpd2RuIFnDOVAhRSByLkG3JO69VS5?	M{[1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFg{Lz5zOUW0NVQ5OzxxYU6=
gastric cancer cells	M2PBPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX:3NkBpenN?	MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDnZZN1emmlIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5?	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
lung cancer cells	M2LB[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUX5fJJTPzJiaILz	MljkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gcJVv\yClYX7j[ZIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAxNjB4NjFOwG0v	MnjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
colon cancer cells	NGLIUXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVi3NkBpenN?	NFPGZ3NIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSByLkC2OkDPxE1w	M4PFclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NFg6Lz5{MEi4OFA5QTxxYU6=
HT-29	M2PzR2N6fG:2b4jpZ4l1gSCjc4PhfS=>			MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODB3OTFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
A549	MnvGR5l1d3SxeHnjbZR6KGG\|c3H5			NYjBVo9vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyxiSVO1NEA:KDBwMES3JO69VS5?	MmL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C4OlQoRjJzNEewPFY1RC:jPh?=
PC3	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		NGTo[484OiCqcoO=	NUX1em5OS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGW6cILld5NqdmdiYXzwbIE2[mW2YUOgbY51\We{aX6gZZN{\XO\|ZXSgZZMh[2WubDDzeZJ3cX[jbDDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNFI3KM7:TT6=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3OUK0Okc,OjJ7NUmyOFY9N2F-
A2780	NXG5SJFNS3m2b4TvfIlkcXS7IHHzd4F6		M3roSVczKGi{cx?=	MnfvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMhd3[ncnX4dJJme3OrbnegZYxxcGF3YnX0ZVMhcW62ZXfybY4h[XO\|ZYPz[YQh[XNiY3XscEB{fXK4aY\hcEBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4xODlizszNMi=>	NUO4XZZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OVkzPDZpPkKyPVU6OjR4PD;hQi=>
DU145	M1;yRWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{whUUN3MDC9JFAvODNizszNMi=>	NX;iUWxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O\|g2PDVpPkKzOVc5PTR3PD;hQi=>
HT-29	M1qy[2N6fG:2b4jpZ4l1gSCjc4PhfS=>			NEHXboJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyxiSVO1NEA:KDBwMEOg{txONg>?	NV;ZVmpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O\|g2PDVpPkKzOVc5PTR3PD;hQi=>
L1210	M3zqRmN6fG:2b4jpZ4l1gSCjc4PhfS=>			MnHKR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMtKEmFNUCgQUAxNjB2IN88UU4>	M2fOblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUe4OVQ2Lz5{M{W3PFU1PTxxYU6=
DU145	NHzRSoxEgXSxdH;4bYNqfHliYYPzZZk>		NHntdVM4OiCqcoO=	M3HVO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNVEh\|ryPLh?=	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MkK5PFEoRjJ\|NkKyPVgyRC:jPh?=
DU145	NWTQSIlpTnWwY4Tpc44h[XO\|YYm=	MmPVNE4yKHSxIECuOUB2VQ>?	NXewXHpZOjRiaILz	M17VUGlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczD1dJJm\3WuYYTpc44hd2ZicEKxe4FnOSCneIDy[ZN{cW:wIHH0JFAvOSC2bzCwMlUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NHjOO\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[yNlk5OSd-MkO2NlI6QDF:L3G+
A549	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		MofSN{Bl[Xm\|	NVnoW4tjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB\|IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNFI4OiEQvF2u	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{OUi3NEc,OjR3Mkm4O\|A9N2F-
HCT116	M{TMbmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlHwN{Bl[Xm\|	M1X2cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB\|IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wN\|Eh\|ryPLh?=	NV\PSII1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
HT-29	MmLFR5l1d3SxeHnjbZR6KGG\|c3H5		NU\GSHg5OyCmYYnz	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA{KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5zME[2O{DPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{OUi3NEc,OjR3Mkm4O\|A9N2F-
HCT116	NF\2cI9EgXSxdH;4bYNqfHliYYPzZZk>			NUTqfHRIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|LDDJR\|UxKD1iMD6xOlYh\|ryPLh?=	M1vublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK5PFcxLz5{NEWyPVg4ODxxYU6=
MDA-MB-231	NF3xcphEgXSxdH;4bYNqfHliYYPzZZk>			MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|LDDJR\|UxKD1iMD6xO\|Yh\|ryPLh?=	NFnFOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
A549	NV\oOnRFS3m2b4TvfIlkcXS7IHHzd4F6			M334TWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjJ3OTFOwG0v	MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O\|AoRjJ2NUK5PFcxRC:jPh?=
HEK293	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn;lO\|IhcHK\|	M1uxZ2lvfHKrboPpZ{BkgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmJNUCgQUAxNjByNTFOwG0v	MlnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{KwOVUoRjJ3MkeyNFU2RC:jPh?=
HCT116	Ml3yR5l1d3SxeHnjbZR6KGG\|c3H5		M4W1elczKGi{cx?=	MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVAhRSByLkCwOFI5KM7:TT6=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUO1PUc,OjV6M{WzOVk9N2F-
HT-29	M4G2O2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NVm5UVBGPzJiaILz	MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiSVO1NEA:KDBwMEG4OVQh\|ryPLh?=	M{nJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|U6Lz5{NUizOVM2QTxxYU6=
HCT15	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		NVLG[pRWPzJiaILz	NWXBUWlLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
U251	M3TaNmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUC3NkBpenN?	NGLNSoFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCyNUDPxE1w	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
U87MG	MojRR5l1d3SxeHnjbZR6KGG\|c3H5		M4KyXlczKGi{cx?=	NF\OOGpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wN{DPxE1w	MlHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO\|YxRC:jPh?=
HT-29	M2m1WGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVS3NkBpenN?	NIS5bpNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wOVQh\|ryPLh?=	M1Phe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
MCF7	M4joPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NE\CcVI4OiCqcoO=	M4LueWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwNUG1JO69VS5?	NXvPZpJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
MDA-MB-231	M3z5RWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoHkO\|IhcHK\|	NWD2cW04S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOS57NzFOwG0v	M4LjVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
NCI-H460	NWHD[W44S3m2b4TvfIlkcXS7IHHzd4F6		MmryNlQhcHK\|	NVywSGdLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgdJJmfHKnYYTl[EBnd3JiMkSgbJJ{KHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3IN88UU4>	NF;zOFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NFk6Pyd-MkizOVA6QTd:L3G+
NCI-H460	MnzDR5l1d3SxeHnjbZR6KGG\|c3H5		NFrS[3gzPCCqcoO=	MmrmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh\|ryPLh?=	NWD6[4p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
HT-29	MojsR5l1d3SxeHnjbZR6KGG\|c3H5		NHrlXnEzPCCqcoO=	M1TDOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj63OEDPxE1w	NVTtWm86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
HT-29	NX7ublN7S3m2b4TvfIlkcXS7IHHzd4F6		NIT2cWIzPCCqcoO=	MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BxemW2cnXheIVlKG[xcjCyOEBpenNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55MTFOwG0v	NH7WOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NFk6Pyd-MkizOVA6QTd:L3G+
NCI-H460	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		M1PLZVczKGi{cx?=	M3j4c2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDy[YR2[3Srb36geY5l\XJiaInwc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMES3JO69VS5?	M1jne\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
NCI-H460	NWTqVYppS3m2b4TvfIlkcXS7IHHzd4F6		MmXBO\|IhcHK\|	NWnidWxPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJJJm\HWldHnvckB2dmSncjDuc5Jud3irYzDjc45lcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFUh\|ryPLh?=	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MX63NkBpenN?	M2PNSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCC{ZXT1Z5Rqd25idX7k[ZIhdm:{bX;4bYMh[2:wZHn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v	NYK3[m1vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
HT-29	Mo\jR5l1d3SxeHnjbZR6KGG\|c3H5		NYGwd5BzPzJiaILz	Ml;DR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKHKnZIXjeIlwdiC3bnTldkBpgXCxeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOTlizszNMi=>	NY[2Tm41RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
TC32	NHXTdlZyUFSVIHHzd4F6			MkHydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NWrNeFNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NGL0U4FyUFSVIHHzd4F6			M1PQTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NFrLWY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	Mnz0dWhVWyCjc4PhfS=>			M1u5PJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MXnxTHRUKGG\|c3H5			MofVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NIrsXY1yUFSVIHHzd4F6			NGHWW4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MoPrdWhVWyCjc4PhfS=>			MlPkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NXj4VYJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MVPxTHRUKGG\|c3H5			M1LMepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M{jxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NGWzXolyUFSVIHHzd4F6			MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NVjQfYZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NEHtTGVyUFSVIHHzd4F6			M2TLZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NHva[pVyUFSVIHHzd4F6			NGDoVY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NH;afXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NVvucYszeUiWUzDhd5NigQ>?			M3TSWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NX;qUJRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MUjxTHRUKGG\|c3H5			NUjybZdueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NEnafWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MUjxTHRUKGG\|c3H5			NFXs[\|hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NVzDeXJNeUiWUzDhd5NigQ>?			NYP1U2o{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M4jEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MXvxTHRUKGG\|c3H5			MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MmHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MXfxTHRUKGG\|c3H5			M1jURZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M4XSb5FJXFNiYYPzZZk>			NH[xc\|NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	M4X1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NIj4UWVyUFSVIHHzd4F6			M1fVSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NV[3W3VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	NHiwb45yUFSVIHHzd4F6			NI\L[nJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	NWDZcWdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NF;h[FVyUFSVIHHzd4F6			MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	M2HZfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NWfoUJF5eUiWUzDhd5NigQ>?			M1;WNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NFPqUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NF24O4tyUFSVIHHzd4F6			NYTuVVd{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NEXYcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NXn3S2N7eUiWUzDhd5NigQ>?			NYjKPVhseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NF65TIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NEnMTnhyUFSVIHHzd4F6			Ml;adWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	M33sd5FJXFNiYYPzZZk>			NFK0OpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NEfNZZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HCT116	NFu2fXVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NELNfoQ4OiCqcoO=	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNFA4QCEQvF2u	NVLRUotYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxNVU1QTJpPkOwNVE2PDl{PD;hQi=>
A549	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{[zdVczKGi{cx?=	Mn3TRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCwNVYzKM7:TT6=	MlO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzMUW0PVIoRjNyMUG1OFkzRC:jPh?=
MCF7	MoTQR5l1d3SxeHnjbZR6KGG\|c3H5		M1vUUlczKGi{cx?=	NYPEbJk3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFAxOSEQvF2u	NHfTZm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEG2PVA{QCd-M{CxOlkxOzh:L3G+
A549	MV7DfZRwfG:6aXPpeJkh[XO\|YYm=		NEjoeHk4OiCqcoO=	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5{IN88UU4>	NIGwbY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEG2PVA{QCd-M{CxOlkxOzh:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-Chk1 / Chk1 / Topo I	18509065
Growth inhibition assay	Cell viability	25759163

In vivo

After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. ^[2]

Protocol (from reference)

Kinase Assay:^[1]

Topoisomerase I Assay:
One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl₂, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na₂HPO₄, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH₂PO₄, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.

Cell Research:^[3]

Cell lines: A-172, U-87, and LA-567
Concentrations: 0 -1000 nM
Incubation Time: 48 h
Method: MTT assay
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	21 mg/mL (53.51 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	392.4
Formula	C₂₂H₂₀N₂O₅
CAS No.	86639-52-3
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

Download SN-38 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05101096	Recruiting	Drug: Sacituzumab Govitecan-hziy	Advanced Solid Tumors or Triple-negative Breast Cancer	Gilead Sciences	October 20 2021	Phase 1\|Phase 2
NCT04866641	Recruiting	Drug: T-1201 Injection 100 mg Kit	Advanced Solid Tumor	Taivex Therapeutics Corporation	June 24 2021	Phase 1
NCT04617522	Recruiting	Drug: Sacituzumab Govitecan-hziy	Advanced or Metastatic Solid Tumor\|Liver Failure	Gilead Sciences	April 6 2021	Phase 1
NCT03995706	Recruiting	Drug: Sacituzumab Govitecan	Glioblastoma	The University of Texas Health Science Center at San Antonio\|Gilead Sciences	July 17 2019	Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):